The FDA has approved the first drug specifically developed to treat postpartum depression; a new study links frequent and high-potency marijuana use to psychosis; and the Mississippi Senate has passed its heartbeat abortion ban.
The FDA approved Sage Therapeutics’ brexanolone (Zulresso), the first drug specifically developed to treat postpartum depression, reported The Associated Press. The intravenous drug, administered over 2.5 days, comes with an estimated price tag of $34,000 without insurance. A study assessing the drug found that when new mothers with moderate to severe depression took brexanolone, half stopped feeling depressed after 2.5 days, which was double the rate seen with those taking placebo.
As states around the country continue to take steps toward legalizing marijuana, a new study from The Lancet Psychiatry is warning of a health risk associated with frequent use: psychosis. According to the study, high frequency of daily marijuana use and high-potency marijuana increases the risk of a psychotic disorder, with daily marijuana users being 3.2 times more likely to have a psychotic disorder than never users and high potency users being 1.6 times more likely.
The Mississippi Senate passed its heartbeat abortion ban, which could bar abortion as early as 6 weeks into a women’s pregnancy. Fifteen Democrats voted against the bill. Governor Phil Bryant, R-Mississippi, has signaled that he will sign the legislation. If signed, the state will have the most restrictive abortion policy in the United States, although other states are debating similar legislation, reported Mississippi Today.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More